Business Daily Media

Men's Weekly

.

Yingli Pharma Announces NMPA Approval of New Anti-cancer Drug Linperlisib

The first highly selective PI3Kδ inhibitor in China

SHANGHAI, CHINA - Media OutReach - 9 November 2022 - Shanghai Yingli Pharmaceutical Co., Ltd. (the "Company" or "Yingli Pharma") is pleased to announce that linperlisib, trade name因他瑞®, a novel phosphoinositide 3-kinase delta (PI3Kδ) inhibitor, has been approved by the National Medical Products Administration (NMPA) of China on November 9 for the treatment of relapsed/refractory follicular lymphoma (R/R FL) in patients who have received 2 or more prior systemic therapies. The NDA approval validates Yingli Pharma’s strong innovation capabilities and fulfills the company’s objectives to bring new treatment options to patients and their families.

Picture-12.png
[Photo: NMPA Approval of linperlisib]

Yingli Pharma has entered into strategic partnership with Jiangsu Hengrui Pharmaceuticals Co., Ltd. (“Hengrui Pharma”), a leading pharmaceutical company with well-established oncology sales and marketing network, to commercialize因他瑞® in China.

A safe and effective treatment choice for FL patients

Linperlisib is a next generation phosphoinositide 3-kinase delta (PI3Kδ) inhibitor independently developed by the Company. PI3Kδ plays a key role in the tumor immune cell proliferation and survival, making it a potent target for non-Hodgkins lymphomas. Treatment options for R/R FL patients, a major form of non-Hodgkins lymphoma, are extremely limited in China. In 2020, linperlisib was awarded NMPA Breakthrough Therapy status for the treatment of R/R FL in China. In addition, it received U.S. Food and Drug Administration (FDA) Orphan Drug Designations for FL, Chronic lymphocytic leukemia/ small lymphocytic lymphoma and T cell lymphoma.

In the pivotal R/R FL Phase II clinical trial in China, linperlisib-treated patients had an 79.8% overall response rate, a 96.6% disease control rate, a median Time to Response of 1.9 months, a median Progression Free Survival of 13.4 months, Duration of Response of 12.3 months and a 91.4% overall survival rate at 12 months1. Linperlisib was well-tolerated with a differentiated and manageable safety profile, with low immune-mediated toxicities. In the linperlisib-treated patient safety dataset of the pivotal study, the most common (>15%) non-hematologic treatment related adverse events (TRAE) (Any Grade/ Grade3) were hypertriglyceridemia (25%/3%), ALT elevation (19%/2%), AST elevation (15%/2%), diarrhea (15%/2%), and pneumonia (15%/15%). The most common (>5%) hematologic TRAEs (Grade3) were neutropenia (15%), leukocytopenia (5%), and lymphocytopenia (5%).

“We are pleased to provide a new treatment option for patients with R/R FL with the approval of linperlisib. As linperlisib is the first innovative drug independently developed by Yingli Pharma, the NDA approval is a significant milestone”, said Dr. Xu Zusheng, General Manager and President of R&D of Yingli Pharma, “We would like to thank the patients, clinicians, and scientists for their generosity and great effort in the clinical development of linperlisib. It is a convenient once daily oral drug which demonstrated favorable safety, promising efficacy and great patient compliance. Yingli Pharma looks forward to in-depth collaboration with Hengrui Pharma to bring forth a full commercialization of 因他瑞® and extend the clinical development into additional indications.”

Dr. Lianshan Zhang, Deputy General Manager and President of Global R&D of Hengrui Pharma, said, " We are delighted with the NDA approval of linperlisib (因他瑞) for R/R FL. This approval is an important step for Hengrui Pharm to build a strong hematology franchise with an enriched pipeline. As Hengrui Pharma focuses on patient-centered R&D and innovation, we will continue to evaluate new indications for linperlisib, and combinations with the company's existing products to potentially benefit more patients.”

1. Lugui Qiu et al. 2022EHA.Abstract 1119

Hashtag: #YingliPharma

About Yingli Pharma

Shanghai Yingli Pharmaceutical Co., Ltd. is a technologically innovative biopharmaceutical company founded in 2011 and located in the National Biomedical Industry Base of Shanghai Zhangjiang InnoPark. With the Chinese government promotion of healthcare reforms, the Chinese pharmaceutical industry has gradually transformed to include the biopharmaceutical sector of innovation. The NDA approval of linperlisib is a significant milestone for this national effort and demonstrates the Company’s strong innovation capability for drug development. Yingli Pharma has established a rich and independently-developed pipeline of novel oral agents for oncology and metabolic diseases. The Company has more than ten drugs under development, including more than 100 independent intellectual property rights, with three of the investigational agents in clinical stage in China and abroad.

For more information, please see:


News from Asia

Hong Kong Men Prioritise Tech Over Health, New Study Reveals

AXA Global Healthcare study highlights worrying gaps in how men prioritise their mental and physical health HONG KONG SAR - Media OutReach Newswire - 22 July 2025 - Men in Hong Kong are signi...

Swiss-Belhotel Brisbane Marks Six-Month Milestone

Strategically located next to The Gabba, the 110-room property affirms Swiss-Belhotel International’s growing footprint in AustraliaBRISBANE, AUSTRALIA - Media OutReach Newswire - 22 July 2025 - S...

AUPU’s ARCHIDEX 2025 Triumph: Redefining Home Comfort in SE Asia

KUALA LUMPUR, MALAYSIA - Media OutReach Newswire - 22 July 2025 - ARCHIDEX 2025 wasn't just an exhibition—it was a statement. AUPU, a global leader in home comfort tech, solidified its position as...

Singapore’s most beloved local F&B brands revealed: foodpanda unveils first-ever Local Foodie Heroes Hall of Fame

A delicious tribute to Singapore’s iconic local eats to mark SG60 celebrations – enjoy close to two months of exclusive launch deals SINGAPORE - Media OutReach Newswire - 22 July 2025 - Get ready ...

Encountering Naadam, Experiencing the 35th Grassland Carnival of the Inner Mongolia Autonomous Region

XILINGOL LEAGUE, CHINA - Media OutReach Newswire - 22 July 2025 - Mid-summer breathes life into Inner Mongolia's grassland, where lush pastures glisten after seasonal rains, nourishing herds benea...

Putting People First: ONYX Hospitality Group's Strategy for Sustainable Leadership

By nurturing talent and cultivating a high-impact culture, ONYX redefines hospitality excellence.BANGKOK, THAILAND - Media OutReach Newswire - 22 July 2025 - ONYX Hospitality Group, a leading hosp...

Wel-Bloom Biotech Launches Wel-ROS6. Black Crystal Roselle Sparks a Surge in High-Concentration Anthocyanins

Black Crystal Roselle Anthocyanin Levels Surge 17.7x — Wel-Bloom Biotech Elevates Taiwan’s Global Ingredient Competitiveness Black Crystal Roselle Shakes Up the Anthocyanin Market...

Lee Kuan Yew School of Public Policy Releases Strategic Roadmap for ASEAN's 5G-AI Transformation

New Research Reveals US$130 Billion Economic Opportunity and Outlines Policy Framework to Accelerate Regional Digital Leadership by 2030SINGAPORE - Media OutReach Newswire - 22 July 2025 - The Le...

DFI Retail Group Holdings Limited Half-Year Results For The Six Months Ended 30 June 2025 And Announcement Of Special Dividend

Highlights 39% underlying earnings growth Increased contributions from associates, Health & Beauty and Food Health & Beauty delivered strong like-for-like (LFL...

HeyMax Acquires Hong Kong’s krip to Accelerate Regional Expansion into Loyalty and Rewards Market

HeyMax’s first acquisition fast-tracks its regional expansion, bringing over 6,000 credit card deals offered by over 3,000 merchants, and personalized loyalty experiences to consumers in Hong Kong ...

Baby boomers are driving development feasibility leading to larger apartments

As residential developers continue to grapple with feasibility issues on apartment projects, the sector is struggling to deliver volumes of new st...

Hays launches FY25/26 Salary Guide: ‘Salary Paradox’ deepens as pay rises fail Australians

Rising dissatisfaction with pay, progression and perks is fuelling a new wave of career change in FY25/26, as Australians demand more from employe...

Australian Businesses Still Stuck in the AI Hype Cycle

Data Governance Failures, ROI Gaps and Unclear Strategy Slowing Progress Despite artificial intelligence (AI) dominating headlines and boardroom ag...

How to ensure your manufacturing business survives international tariff turmoil

Optimising your operations in FY2026 will help you combat the challenges of a volatile trading environment. Up, down, in out…Since the commence...

Why Apptio is Enhancing Visibility into AI and Hybrid Cloud

AI investments have become a strategic priority for business with the mindset that if you're not using AI, you're falling behind. But according to...

Beyond borders: Building a scalable strategy for international hiring

For many Australian businesses, growth increasingly depends on thinking beyond local borders.  As wage pressures rise, and specialised talent pool...

Sell by LayBy